This resulted in the validation of two novel PCa biomarkers - GLO1 and NKX3-1 mRNAs that are overexpressed in PCa tissues, known to functionally contribute to the PCa development, and have higher levels in plasma EVs from PCa patients than BPH patients. The gene discussed is GLO1; the disease is benign prostatic hyperplasia.